尽管有明确证据表明有用,但对2012年KDIGO慢性肾脏病临床实践指南的依从性仍较低
本研究利用美国与英国数据库数据,评估慢性肾脏病患者按2012年KDIGO指南分类的特征与结局。在123807例合格患者中,仅8.6%有两次eGFR测量者至少有一次UACR测量。心衰、高血压和2型糖尿病患病率随白蛋白尿增加而升高,死亡及不良心血管和肾脏结局发生率随基线eGFR下降而升高,尤其随白蛋白尿增加而升高。
要点
- 仅8.6%有两次eGFR测量的患者至少有一次UACR测量。
- 心衰、高血压和2型糖尿病患病率随白蛋白尿增加而升高。
- 死亡及不良心血管和肾脏结局发生率随基线eGFR下降而升高,尤其随白蛋白尿增加而升高。
核心结论
- 白蛋白尿监测对于慢性肾脏病的最佳风险分层至关重要,研究结果强调临床实践中需要更频繁地进行UACR检测。
研究设计与样本
- 利用DISCOVER CKD(NCT04034992)研究数据,从美国综合有限索赔与电子健康记录数据集和TriNetX数据库,以及英国临床实践研究数据链链接医院Episode统计和英国国家统计局数据库提取数据。
- 纳入年龄≥18岁、自2008年1月起通过两次连续eGFR测量(间隔≥90天,最长730天)且eGFR为5至<75 ml/min/1.73 m2识别的慢性肾脏病患者,索引日期为第二次eGFR测量日期,使用最接近索引日期的UACR测量进行分类。
- 共纳入123807例合格患者。
主要发现
- 在所有数据库中,仅8.6%有两次eGFR测量的患者至少有一次UACR测量。
- 心衰、高血压和2型糖尿病患病率随白蛋白尿增加而升高。
- 死亡及不良心血管和肾脏结局的发生率随基线eGFR下降而升高,尤其随白蛋白尿增加而升高。
- 索引后每年eGFR和UACR检测的中位数次数在各数据库分别为1.6至2.5次和0.5至0.6次。
- 2012年KDIGO指南发布后,UACR检测频率未见明显增加。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Kidney Disease: Improving Global Outcomes (KDIGO) 2012 guidelines classify chronic kidney disease (CKD) risk or prognosis using estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (UACR). We assessed patient characteristics and outcomes according to the KDIGO classification, using data from DISCOVER CKD (NCT04034992). METHODS: Data were extracted from the US integrated Limited Claims and Electronic Health Record Dataset and TriNetX databases, and the UK Clinical Practice Research Datalink linked to Hospital Episode Statistics and Office for National Statistics databases. Eligible patients were aged ≥18 years with CKD, and identified by 2 consecutive eGFR measures (5 to <75 ml/min/1.73 m2; ≥90 days apart [maximum 730]) from January 2008. Index date was the second eGFR measurement; patients were categorized using the UACR measure closest to the index. Outcomes included patient characteristics, eGFR or UACR measurement frequency, and clinical outcomes per baseline KDIGO classification. RESULTS: Across databases, only 8.6% of patients with 2 eGFR measures had ≥1 UACR measures. Among 123,807 eligible patients, prevalence of heart failure, hypertension, and type 2 diabetes increased with increasing albuminuria. Incidence rates of mortality and adverse cardiovascular and renal outcomes increased with declining baseline eGFR, and particularly with increasing albuminuria. Median number of eGFR and UACR tests per year post-index ranged from 1.6 to 2.5 and 0.5 to 0.6, respectively, across databases; there was no clear increase in UACR testing frequency following the KDIGO 2012 guidelines. CONCLUSION: Albuminuria monitoring is critical for optimal risk stratification in CKD, and our findings highlight an imperative for more regular UACR testing in clinical practice.
引用
- James G, Garcia Sanchez JJ, Carrero JJ, et al. Low Adherence to Kidney Disease: Improving Global Outcomes 2012 CKD Clinical Practice Guidelines Despite Clear Evidence of Utility. Kidney Int Rep. 2022. PMID: 36090504. doi:10.1016/j.ekir.2022.05.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。